An overview of circulating and urinary biomarkers capable of predicting the transition of acute kidney injury to chronic kidney disease

References

• Almazmomi MA, Esmat A, Naeem A. Acute kidney injury: definition, management, and promising therapeutic target. Cureus. 2023;15:e51228. doi: 10.7759/cureus.51228
   PubMed Web of Science ®Google Scholar
• Chawla LS, Bellomo R, Bihorac A, et al. Acute disease quality initiative workgroup 16. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13:241–257. doi: 10.1038/nrneph.2017.2
   PubMed Web of Science ®Google Scholar
• Levey AS. Defining AKD: the spectrum of AKI, AKD, and CKD. Nephron. 2022;146:302–305. doi: 10.1159/000516647
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 2020;97:1117–1129. doi: 10.1016/j.kint.2020.02.010
   PubMed Web of Science ®Google Scholar
• Lameire NH, Levin A, Kellum JA, et al. Conference participants. harmonizing acute and chronic kidney disease definition and classification: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 2021;100(3):516–526. doi: 10.1016/j.kint.2021.06.028
   PubMed Web of Science ®Google Scholar
• Birkelo BC, Pannu N, Siew ED. Overview of diagnostic criteria and epidemiology of acute kidney injury and acute kidney disease in the critically ill patient. Clin J Am Soc Nephrol. 2022;17:717–735. doi: 10.2215/CJN.14181021
   PubMed Web of Science ®Google Scholar
• Hoste EAJ, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14:607–625. doi: 10.1038/s41581-018-0052-0
   PubMed Web of Science ®Google Scholar
• Jankowski J, Floege J, Fliser D, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157–1172. doi: 10.1161/CIRCULATIONAHA.120.050686
   PubMed Web of Science ®Google Scholar
• Lachance P, Villeneuve PM, Rewa OG, et al. Association between e-alert implementation for detection of acute kidney injury and outcomes: a systematic review. Nephrol Dial Transplant. 2017;32(2):265–272. doi: 10.1093/ndt/gfw424
   PubMed Web of Science ®Google Scholar
• Susantitaphong P, Cruz DN, Cerda J, et al. Acute Kidney Injury Advisory Group of the American Society of Nephrology. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8:1482–1493. doi: 10.2215/CJN.00710113
   PubMed Web of Science ®Google Scholar
• Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3–15. doi: 10.1007/978-981-13-8871-2_1 PMID: 31399958.
   PubMed Web of Science ®Google Scholar
• James MT, Levey AS, Tonelli M, et al. Incidence and prognosis of acute kidney diseases and disorders using an integrated approach to laboratory measurements in a universal health care system. JAMA Netw Open. 2019;2:e191795. doi: 10.1001/jamanetworkopen.2019.1795
   PubMed Web of Science ®Google Scholar
• Vaara ST, Serpa Neto A, Bellomo R, et al. Regional practice variation and outcomes in the standard versus accelerated initiation of renal replacement therapy in acute kidney injury (STARRT-AKI) trial: a post hoc secondary analysis. Crit Care Explor. 2024;6(2):e1053. doi: 10.1097/CCE.0000000000001053
   PubMedGoogle Scholar
• Bufkin KB, Karim ZA, Silva J. Review of the limitations of current biomarkers in acute kidney injury clinical practices. SAGE Open Med. 2024;12:20503121241228446. doi: 10.1177/20503121241228446
   Web of Science ®Google Scholar
• Kellum JA, Romagnani P, Ashuntantang G, et al. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):52. doi: 10.1038/s41572-021-00284-z
   PubMed Web of Science ®Google Scholar
• Yeh TH, Tu KC, Wang HY, et al. From acute to chronic: unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease. Int J Mol Sci. 2024;25(3):1755. doi: 10.3390/ijms25031755
   PubMed Web of Science ®Google Scholar
• Kimmel M, Shi J, Latus J, et al. Association of renal stress/damage and filtration biomarkers with subsequent AKI during hospitalization among patients presenting to the emergency department. Clin J Am Soc Nephrol. 2016;11:938–946. doi: 10.2215/CJN.10551015
   PubMed Web of Science ®Google Scholar
• Elrggal ME, Bajpai D, Tannor EK, et al. Access to nephrology care for pregnancy-related acute kidney injury in low- and lower-middle-income countries: a perspective. Kidney Med. 2023;5(9):100695. doi: 10.1016/j.xkme.2023.100695
   PubMedGoogle Scholar
• Li PK, Burdmann EA, Mehta RL. World kidney day steering committee 2013. Acute kidney injury: global health alert. Transplantation. 2013;95(5):653–657. doi: 10.1097/TP.0b013e31828848bc PMID: 23503499.
   PubMed Web of Science ®Google Scholar
• Cerdá J, Bagga A, Kher V, et al. The contrasting characteristics of acute kidney injury in developed and developing countries. Nat Clin Pract Nephrol. 2008;4(3):138–153. doi: 10.1038/ncpneph0722
   PubMedGoogle Scholar
• Saxena A, Meshram SV. Predictors of mortality in acute kidney injury patients admitted to medicine intensive care unit in a rural tertiary care hospital. Indian J Crit Care Med. 2018;22:231–237. doi: 10.4103/ijccm.IJCCM_462_17
   PubMedGoogle Scholar
• Lydia A, Rebecca RV, Sedono R, et al. Factors associated with mortality of intensive care unit patients with acute kidney injury at cipto mangunkusumo national central general hospital. Acta Med Indones. 2019;51:324–330. PMID: 32041916.
   PubMed Web of Science ®Google Scholar
• Medina KRP, Jeong JC, Ryu JW, et al. Comparison of outcomes of mild and severe community- and hospital-acquired acute kidney injury. Yonsei Med J. 2022;63(10):902–907. doi: 10.3349/ymj.2021.0238
   PubMed Web of Science ®Google Scholar
• Bendall AC, See EJ, Toussaint ND, et al. Community-acquired versus hospital-acquired acute kidney injury at a large Australian metropolitan quaternary referral centre: incidence, associations and outcomes. Intern Med J. 2023;53(8):1366–1375. doi: 10.1111/imj.15787
   PubMed Web of Science ®Google Scholar
• Der Mesropian PJ, Kalamaras JS, Eisele G, et al. Long-term outcomes of community-acquired versus hospital-acquired acute kidney injury: a retrospective analysis. Clin Nephrol. 2014;81(3):174–184. doi: 10.5414/CN108153
   PubMed Web of Science ®Google Scholar
• Ehmann MR, Klein EY, Zhao X, et al. Epidemiology and clinical outcomes of community-acquired acute kidney injury in the emergency department: a multisite retrospective cohort study. Am J Kidney Dis. 2023;83(6):S0272–6386(23)00945–9. doi: 10.1053/j.ajkd.2023.10.009
   Google Scholar
• Koyner JL, Mackey RH, Rosenthal NA, et al. Clinical outcomes of persistent severe acute kidney injury among patients with kidney disease improving global outcomes stage 2 or 3 acute kidney injury. Am J Nephrol. 2022;53:816–825. doi: 10.1159/000528158
   PubMed Web of Science ®Google Scholar
• Inokuchi R, Hara Y, Yasuda H, et al. Differences in characteristics and outcomes between community- and hospital-acquired acute kidney injury: a systematic review and meta-analysis. Clin Nephrol. 2017;88:167–182. doi: 10.5414/CN109011
   PubMedGoogle Scholar
• Gross C, Miao Jonasson J, Buchebner D, et al. Prognosis and mortality within 90 days in community-acquired acute kidney injury in the Southwest of Sweden. BMC Nephrol. 2023;24:171. doi: 10.1186/s12882-023-03221-2
   PubMed Web of Science ®Google Scholar
• Neyra JA, Ortiz-Soriano V, Liu LJ, et al. Prediction of mortality and major adverse kidney events in critically ill patients with acute kidney injury. Am J Kidney Dis. 2023;81:36–47. doi: 10.1053/j.ajkd.2022.06.004
   PubMed Web of Science ®Google Scholar
• Luo X, Yan P, Zhang N, et al. Early recovery status and outcomes after sepsis-associated acute kidney injury in critically ill patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022;47:535–545. doi: 10.11817/j.issn.1672-7347.2022.210368
   PubMedGoogle Scholar
• Bai Y, Li Y, Jin J, et al. Effects of early recovery of renal function on adverse renal outcomes and mortality in patients with acute kidney injury: a systematic review and meta-analysis. Int Urol Nephrol. 2024;56(7):2421–2430. doi: 10.1007/s11255-024-03974-1
   PubMed Web of Science ®Google Scholar
• Livingston MJ, Shu S, Fan Y, et al. Tubular cells produce FGF2 via autophagy after acute kidney injury leading to fibroblast activation and renal fibrosis. Autophagy. 2023;19(1):256–277. doi: 10.1080/15548627.2022.2072054
   PubMed Web of Science ®Google Scholar
• Gurevich VV, Gurevich EV. GPCR signaling regulation: the role of GRKs and arrestins. Front Pharmacol. 2019;10:125. doi: 10.3389/fphar.2019.00125
   PubMed Web of Science ®Google Scholar
• Valiño-Rivas L, Cuarental L, Ceballos MI, et al. Growth differentiation factor-15 preserves klotho expression in acute kidney injury and kidney fibrosis. Kidney Int. 2022;101:1200–1215. doi: 10.1016/j.kint.2022.02.028
   PubMed Web of Science ®Google Scholar
• Zhan X, Kaoud TS, Kook S, et al. JNK3 enzyme binding to arrestin-3 differentially affects the recruitment of upstream mitogen-activated protein (MAP) kinase kinases. J Biol Chem. 2013;288(40):28535–28547. doi: 10.1074/jbc.M113.508085
   PubMed Web of Science ®Google Scholar
• Haeusgen W, Herdegen T, Waetzig V. The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7. Eur J Cell Biol. 2011;90(6–7):536–544. doi: 10.1016/j.ejcb.2010.11.008
   PubMed Web of Science ®Google Scholar
• Zhao B, Sun L, Haas M, et al. PP2A regulates upstream members of the c-jun N-terminal kinase mitogen-activated protein kinase signaling pathway. Shock. 2008;29:181–188. doi: 10.1097/SHK.0b013e318070c840
   PubMed Web of Science ®Google Scholar
• Chen L, Liu L, Yin J, et al. Hydrogen peroxide-induced neuronal apoptosis is associated with inhibition of protein phosphatase 2A and 5, leading to activation of MAPK pathway. Int J Biochem Cell Biol. 2009;41:1284–1295. doi: 10.1016/j.biocel.2008.10.029
   PubMed Web of Science ®Google Scholar
• Mennuni S, Rubattu S, Pierelli G, et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28:74–79. doi: 10.1038/jhh.2013.55
   PubMed Web of Science ®Google Scholar
• Berezin A. Endogenous vascular repair system in cardiovascular disease: the role of endothelial progenitor cells. AMJ. 2019;12:42–48. doi: 10.21767/AMJ.2018.3464
   Google Scholar
• Jover B, Mimran A. Nitric oxide inhibition and renal alterations. J Cardiovasc Pharmacol. 2001;38:S65–70. doi: 10.1097/00005344-200111002-00016
   PubMed Web of Science ®Google Scholar
• Doleželová Š, Jíchová Š, Husková Z, et al. Progression of hypertension and kidney disease in aging fawn-hooded rats is mediated by enhanced influence of renin–angiotensin system and suppression of nitric oxide system and epoxyeicosanoids. Clin Exp Hypertens. 2016;38(7):644–651. doi: 10.1080/10641963.2016.1182182
   PubMed Web of Science ®Google Scholar
• Eshima K, Hirooka Y, Shigematsu H, et al. Angiotensin in the nucleus tractus solitarii contributes to neurogenic hypertension caused by chronic nitric oxide synthase inhibition. Hypertension. 2000;36:259–263. doi: 10.1161/01.hyp.36.2.259
   PubMed Web of Science ®Google Scholar
• Patschan D, Patschan S, Müller GA. Inflammation and microvasculopathy in renal ischemia reperfusion injury. J Transplant. 2012;2012:764154. doi: 10.1155/2012/764154
   PubMedGoogle Scholar
• Zhang JQ, Li YY, Zhang XY, et al. Cellular senescence of renal tubular epithelial cells in renal fibrosis. Front Endocrinol (Lausanne). 2023;14:1085605. doi: 10.3389/fendo.2023.1085605
   PubMed Web of Science ®Google Scholar
• Berezin AE, Berezin AA. Extracellular endothelial cell-derived vesicles: emerging role in cardiac and vascular remodeling in heart failure. Front Cardiovasc Med. 2020;7:47. doi: 10.3389/fcvm.2020.00047
   PubMed Web of Science ®Google Scholar
• Luo C, Zhou S, Zhou Z, et al. Wnt9a promotes renal fibrosis by accelerating cellular senescence in tubular epithelial cells. J Am Soc Nephrol. 2018;29:1238–1256. doi: 10.1681/ASN.2017050574
   PubMed Web of Science ®Google Scholar
• Zhang X, Li L, Tan H, et al. Klotho-derived peptide 1 inhibits cellular senescence in the fibrotic kidney by restoring klotho expression via posttranscriptional regulation. Theranostics. 2024;14(1):420–435. doi: 10.7150/thno.89105
   PubMed Web of Science ®Google Scholar
• Berezin AE, Berezin AA. Impaired function of fibroblast growth factor 23/Klotho protein axis in prediabetes and diabetes mellitus: promising predictor of cardiovascular risk. Diabetes Metab Syndr. 2019;13(4):2549–2556. doi: 10.1016/j.dsx.2019.07.018
   PubMed Web of Science ®Google Scholar
• Miao J, Huang J, Luo C, et al. Klotho retards renal fibrosis through targeting mitochondrial dysfunction and cellular senescence in renal tubular cells. Physiol Rep. 2021;9(2):e14696. doi: 10.14814/phy2.14696
   PubMed Web of Science ®Google Scholar
• Schelling JR. Tubular atrophy in the pathogenesis of chronic kidney disease progression. Pediatr Nephrol. 2016;31:693–706. doi: 10.1007/s00467-015-3169-4
   PubMed Web of Science ®Google Scholar
• Lee K, He JC. AKI-to-CKD transition is a potential mechanism for non-albuminuric diabetic kidney disease. Fac Rev. 2022;11:21. doi: 10.12703/r/11-21
   PubMedGoogle Scholar
• Lertussavavivat T, Kulvichit W, Peerapornratana S, et al. The epidemiology and long-term outcomes of acute kidney disease in a resource-limited setting. J Nephrol. 2022;35:2283–2292. doi: 10.1007/s40620-022-01328-7
   PubMed Web of Science ®Google Scholar
• Maekawa H, Inagi R. Pathophysiological role of organelle stress/crosstalk in AKI-to-CKD transition. Semin Nephrol. 2019;39:581–588. doi: 10.1016/j.semnephrol.2019.10.007
   PubMed Web of Science ®Google Scholar
• Kwiatkowska E, Kwiatkowski S, Dziedziejko V, et al. Renal microcirculation injury as the main cause of ischemic acute kidney injury development. Biology (Basel). 2023;12:327. doi: 10.3390/biology12020327
   PubMedGoogle Scholar
• Zhao ZB, Marschner JA, Iwakura T, et al. Tubular epithelial cell HMGB1 promotes AKI-CKD transition by sensitizing cycling tubular cells to oxidative stress: a rationale for targeting HMGB1 during AKI recovery. J Am Soc Nephrol. 2023;34:394–411. doi: 10.1681/ASN.0000000000000024
   PubMed Web of Science ®Google Scholar
• Pasternak M, Liu P, Quinn R, et al. Association of albuminuria and regression of chronic kidney disease in adults with newly diagnosed moderate to severe chronic kidney disease. JAMA Netw Open. 2022;5:e2225821. doi: 10.1001/jamanetworkopen.2022.25821
   PubMed Web of Science ®Google Scholar
• Lekawanvijit S, Krum H. Cardiorenal syndrome: role of protein-bound uremic toxins. J Ren Nutr. 2015;25:149–154. doi: 10.1053/j.jrn.2014.10.009
   PubMed Web of Science ®Google Scholar
• Barreto FC, Stinghen AE, de Oliveira RB, et al. The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. J Bras Nefrol. 2014;36(2):221–235. doi: 10.5935/0101-2800.20140033
   PubMedGoogle Scholar
• Okada K, Matsumoto K, Takahashi S. Uremic toxins adsorbed by AST-120 promote tubular hypertrophy and interstitial fibrosis in nephrectomized rats. Kidney Blood Press Res. 2005;28:8–13. doi: 10.1159/000080935
   PubMed Web of Science ®Google Scholar
• Risso MA, Sallustio S, Sueiro V, et al. The importance of tubular function in chronic kidney disease. Int J Nephrol Renovasc Dis. 2019;12:257–262. doi: 10.2147/IJNRD.S216673
   PubMed Web of Science ®Google Scholar
• André C, Bodeau S, Kamel S, et al. The AKI-to-CKD transition: the role of uremic toxins. Int J Mol Sci. 2023;24(22):16152. doi: 10.3390/ijms242216152
   PubMed Web of Science ®Google Scholar
• Chen JH, Chao CT, Huang JW, et al. Early elimination of uremic toxin ameliorates AKI-to-CKD transition. Clin Sci (Lond). 2021;135:2643–2658. doi: 10.1042/CS20210858
   PubMed Web of Science ®Google Scholar
• Hanna RM, Streja E, Kalantar-Zadeh K. Burden of anemia in chronic kidney disease: beyond erythropoietin. Adv Ther. 2021;3(1):52–75. doi: 10.1007/s12325-020-01524-6
   Google Scholar
• Liu H, Li Y, Xiong J. The role of hypoxia-inducible factor-1 alpha in renal disease. Molecules. 2022;27:7318. doi: 10.3390/molecules27217318
   PubMed Web of Science ®Google Scholar
• Góes MA, Iizuka IJ, Quinto BM, et al. Serum soluble-fas, inflammation, and anemia in acute kidney injury. Artif Organs. 2018;42:E283–E289. doi: 10.1111/aor.12019
   PubMed Web of Science ®Google Scholar
• Zhang P, Tong Y, Yuan D, et al. Association of high-sensitivity C-reactive protein and anemia with acute kidney injury in neonates. Front Pediatr. 2022;10:882739. doi: 10.3389/fped.2022.882739
   PubMed Web of Science ®Google Scholar
• Zarbock A, Koyner JL, Hoste EAJ, et al. Update on perioperative acute kidney injury. Anesth Analg. 2018;127:1236–1245. doi: 10.1213/ANE.0000000000003741
   PubMed Web of Science ®Google Scholar
• Chin K, Joo H, Jiang H, et al. Importance of assessing biomarkers and physiological parameters of anemia-induced tissue hypoxia in the perioperative period. Braz J Anesthesiol. 2023;73(2):186–197. doi: 10.1016/j.bjane.2022.10.004
   PubMedGoogle Scholar
• Li Q, Pan S. Contrast-associated acute kidney injury: advances and challenges. Int J Gen Med. 2022;15:1537–1546. doi: 10.2147/IJGM.S341072
   PubMed Web of Science ®Google Scholar
• Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. JAMA Netw Open. 2020;3(10):e2019209. doi: 10.1001/jamanetworkopen.2020.19209
   PubMed Web of Science ®Google Scholar
• Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr. 2010;20:S2–6. doi: 10.1053/j.jrn.2010.05.002
   PubMed Web of Science ®Google Scholar
• Cheng TH, Ma MC, Liao MT, et al. Indoxyl sulfate, a tubular toxin, contributes to the development of chronic kidney disease. Toxins (Basel). 2020;12:684. doi: 10.3390/toxins12110684
   PubMed Web of Science ®Google Scholar
• Shen WC, Liang CJ, Huang TM, et al. Indoxyl sulfate enhances IL-1β-induced E-selectin expression in endothelial cells in acute kidney injury by the ROS/MAPKs/NFκB/AP-1 pathway. Arch Toxicol. 2016;90:2779–2792. doi: 10.1007/s00204-015-1652-0
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Tanaka R, Donouchi M, et al. Vascular endothelial dysfunction in the thoracic aorta of rats with ischemic acute kidney injury: contribution of indoxyl sulfate. Oxid Med Cell Longev. 2022;2022:1–9. doi: 10.1155/2022/7547269
   Web of Science ®Google Scholar
• Niwa T, Shimizu H. Indoxyl sulfate induces nephrovascular senescence. J Ren Nutr. 2012;22:102–106. doi: 10.1053/j.jrn.2011.10.032
   PubMed Web of Science ®Google Scholar
• Shimizu H, Yisireyili M, Nishijima F, et al. Stat3 contributes to indoxyl sulfate-induced inflammatory and fibrotic gene expression and cellular senescence. Am J Nephrol. 2012;36:184–189. doi: 10.1159/000341515
   PubMed Web of Science ®Google Scholar
• Saito S, Shimizu H, Yisireyili M, et al. Indoxyl sulfate-induced activation of (pro)renin receptor is involved in expression of TGF-β1 and α-smooth muscle actin in proximal tubular cells. Endocrinology. 2014;155:1899–1907. doi: 10.1210/en.2013-1937
   PubMed Web of Science ®Google Scholar
• Albert C, Haase M, Albert A, et al. Biomarker-guided risk assessment for acute kidney injury: time for clinical implementation? Ann Lab Med. 2021;41(1):1–15. doi: 10.3343/alm.2021.41.1.1
   PubMed Web of Science ®Google Scholar
• Gross P, Massy ZA, Henaut L, et al. Para-cresyl sulfate acutely impairs vascular reactivity and induces vascular remodeling. J Cell Physiol. 2015;230:2927–2935. doi: 10.1002/jcp.25018
   PubMed Web of Science ®Google Scholar
• Gouroju S, Pvlns R, Bitla AR, et al. Role of gut-derived uremic toxins on oxidative stress and inflammation in patients with chronic kidney disease. Indian J Nephrol. 2017;27(5):359–364. doi: 10.4103/ijn.IJN_71_17
   PubMedGoogle Scholar
• Six I, Flissi N, Lenglet G, et al. Uremic toxins and vascular dysfunction. Toxins (Basel). 2020;12:404. doi: 10.3390/toxins12060404
   PubMed Web of Science ®Google Scholar
• Caillard P, Bennis Y, Six I, et al. The role of gut-derived, protein-bound uremic toxins in the cardiovascular complications of acute kidney injury. Toxins (Basel). 2022;14:336. doi: 10.3390/toxins14050336
   PubMed Web of Science ®Google Scholar
• Ahmed S, de Vries JC, Lu J, et al. Animal models for studying protein-bound uremic toxin removal – a systematic review. Int J Mol Sci. 2023;24(17):13197. doi: 10.3390/ijms241713197
   PubMed Web of Science ®Google Scholar
• Krieter DH, Kerwagen S, Rüth M, et al. Differences in dialysis efficacy have limited effects on protein-bound uremic toxins plasma levels over time. Toxins (Basel). 2019;11:47. doi: 10.3390/toxins11010047
   PubMed Web of Science ®Google Scholar
• Krieter DH, Devine E, Körner T, et al. Haemodiafiltration at increased plasma ionic strength for improved protein-bound toxin removal. Acta Physiol (Oxf). 2017;219:510–520. doi: 10.1111/apha.12730
   PubMed Web of Science ®Google Scholar
• Liu T, Li Q, Jin Q, et al. Targeting HMGB1: a potential therapeutic strategy for chronic kidney disease. Int J Biol Sci. 2023;19(15):5020–5035. doi: 10.7150/ijbs.87964
   PubMed Web of Science ®Google Scholar
• Liu T, Zhao H, Wang Y, et al. Serum high mobility group box 1 as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes. Front Immunol. 2024;15:1334109. doi: 10.3389/fimmu.2024.1334109
   PubMed Web of Science ®Google Scholar
• Mo C, Huang Q, Li L, et al. High-mobility group box 1 and its related receptors: potential therapeutic targets for contrast-induced acute kidney injury. Int Urol Nephrol. 2024;56(7):2291–2299. doi: 10.1007/s11255-024-03981-2
   PubMed Web of Science ®Google Scholar
• Trivedi A, Bose D, Saha P, et al. Prolonged antibiotic use in a preclinical model of gulf war chronic multisymptom-illness causes renal fibrosis-like pathology via increased micro-RNA 21-induced PTEN inhibition that is correlated with low host lachnospiraceae abundance. Cells. 2023;13:56. doi: 10.3390/cells13010056
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Liu A, et al. Erythropoietin derived peptide improved endoplasmic reticulum stress and ischemia-reperfusion related cellular and renal injury. Front Med (Lausanne). 2020;7:5. doi: 10.3389/fmed.2020.00005
   PubMed Web of Science ®Google Scholar
• Ishida M, Ueki M, Morishita J, et al. T-5224, a selective inhibitor of c-Fos/activator protein-1, improves survival by inhibiting serum high mobility group box-1 in lethal lipopolysaccharide-induced acute kidney injury model. J Intensive Care. 2015;3:49. doi: 10.1186/s40560-015-0115-2
   PubMedGoogle Scholar
• Bruchfeld A, Qureshi AR, Lindholm B, et al. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med. 2008;14:109–115. doi: 10.2119/2007-00107.Bruchfeld
   PubMed Web of Science ®Google Scholar
• Zakiyanov O, Kriha V, Vachek J, et al. Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study. BMC Nephrol. 2013;14:245. doi: 10.1186/1471-2369-14-245
   PubMed Web of Science ®Google Scholar
• Zhu N, Yuan W, Zhou Y, et al. High mobility group box protein-1 correlates with microinflammatory state and nutritional status in continuous ambulatory peritoneal dialysis patients. J Artif Organs. 2011;14:125–132. doi: 10.1007/s10047-011-0561-0
   PubMed Web of Science ®Google Scholar
• Marakala V. Neutrophil gelatinase-associated lipocalin (NGAL) in kidney injury – a systematic review. Clin Chim Acta. 2022;536:135–141. doi: 10.1016/j.cca.2022.08.029
   PubMed Web of Science ®Google Scholar
• Alvarez S, Suazo C, Boltansky A, et al. Urinary exosomes as a source of kidney dysfunction biomarker in renal transplantation. Transplant Proc. 2013;45:3719–3723. doi: 10.1016/j.transproceed.2013.08.079
   PubMed Web of Science ®Google Scholar
• Haase M, Bellomo R, Devarajan P, et al. NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54(6):1012–1024. doi: 10.1053/j.ajkd.2009.07.020
   PubMed Web of Science ®Google Scholar
• Zhang A, Cai Y, Wang PF, et al. Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis. Crit Care. 2016;20:41. doi: 10.1186/s13054-016-1212-x
   PubMed Web of Science ®Google Scholar
• Zhou F, Luo Q, Wang L, et al. Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis. Eur J Cardiothorac Surg. 2016;49:746–755. doi: 10.1093/ejcts/ezv199
   PubMed Web of Science ®Google Scholar
• Mahapatro A, Nobakht S, Mukesh S, et al. Evaluating biomarkers for contrast-induced nephropathy following coronary interventions: an umbrella review on meta-analyses. Eur J Med Res. 2024;29:210. doi: 10.1186/s40001-024-01782-y
   PubMed Web of Science ®Google Scholar
• Cappuccilli M, Capelli I, Comai G, et al. Neutrophil gelatinase-associated lipocalin as a biomarker of allograft function after renal transplantation: evaluation of the current status and future insights. Artif Organs. 2018;42:8–14. doi: 10.1111/aor.13039
   PubMed Web of Science ®Google Scholar
• Haase-Fielitz A, Haase M, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury: a critical evaluation of current status. Ann Clin Biochem. 2014;51:335–351. doi: 10.1177/0004563214521795
   PubMed Web of Science ®Google Scholar
• Romejko K, Markowska M, Niemczyk S. The review of current knowledge on neutrophil gelatinase-associated lipocalin (NGAL). Int J Mol Sci. 2023;24:10470. doi: 10.3390/ijms241310470
   PubMed Web of Science ®Google Scholar
• Katagiri M, Takahashi M, Doi K, et al. Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease. Heart Vessels. 2016;31:1595–1602. doi: 10.1007/s00380-015-0776-8
   PubMed Web of Science ®Google Scholar
• Song J, Yu J, Prayogo GW, et al. Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology. Am J Transl Res. 2019;11(3):1219–1229. PMID: 30972157; PMCID: PMC6456506.
   PubMed Web of Science ®Google Scholar
• Yang L, Brooks CR, Xiao S, et al. KIM-1–mediated phagocytosis reduces acute injury to the kidney. J Clin Invest. 2015;125(4):1620–1636. doi: 10.1172/JCI75417
   PubMed Web of Science ®Google Scholar
• Lim AI, Tang SC, Lai KN, et al. Kidney injury molecule-1: more than just an injury marker of tubular epithelial cells? J Cell Physiol. 2013;228(5):917–924. doi: 10.1002/jcp.24267
   PubMed Web of Science ®Google Scholar
• Tanase DM, Gosav EM, Radu S, et al. The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity. Int J Mol Sci. 2019;20:5238. doi: 10.3390/ijms20205238
   PubMed Web of Science ®Google Scholar
• Fazel M, Sarveazad A, Mohamed Ali K, et al. Accuracy of urine kidney injury molecule-1 in predicting acute kidney injury in children; a systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8:e44. PMID: 32309808; PMCID: PMC7159147.
   PubMedGoogle Scholar
• Geng J, Qiu Y, Qin Z, et al. The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis. J Transl Med. 2021;19:105. doi: 10.1186/s12967-021-02776-8
   PubMed Web of Science ®Google Scholar
• Medić B, Rovčanin B, Basta Jovanović G, et al. Kidney injury molecule-1 and cardiovascular diseases: from basic science to clinical practice. Biomed Res Int. 2015;2015:854070. doi: 10.1155/2015/854070
   PubMed Web of Science ®Google Scholar
• Montgomery TA, Xu L, Mason S, et al. Breast regression protein–39/chitinase 3–like 1 promotes renal fibrosis after kidney injury via activation of myofibroblasts. J Am Soc Nephrol. 2017;28(11):3218–3226. doi: 10.1681/ASN.2017010110
   PubMed Web of Science ®Google Scholar
• Huen SC, Parikh CR. Molecular phenotyping of clinical AKI with novel urinary biomarkers. Am J Physiol Renal Physiol. 2015;309(5):F406–13. doi: 10.1152/ajprenal.00682.2014
   PubMed Web of Science ®Google Scholar
• Conroy AL, Hawkes MT, Elphinstone R, et al. Chitinase-3-like 1 is a biomarker of acute kidney injury and mortality in paediatric severe malaria. Malar J. 2018;17(1):82. doi: 10.1186/s12936-018-2225-5
   PubMed Web of Science ®Google Scholar
• Maddens B, Ghesquière B, Vanholder R, et al. Chitinase-like proteins are candidate biomarkers for sepsis-induced acute kidney injury. Mol Cell Proteomics. 2012;11:M111.013094. doi: 10.1074/mcp.M111.013094
   PubMed Web of Science ®Google Scholar
• De Loor J, Decruyenaere J, Demeyere K, et al. Urinary chitinase 3-like protein 1 for early diagnosis of acute kidney injury: a prospective cohort study in adult critically ill patients. Crit Care. 2016;20:38. doi: 10.1186/s13054-016-1192-x
   PubMed Web of Science ®Google Scholar
• Hoste EA, Vaara ST, De Loor J, et al. FINNAKI Study Group. Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort. Crit Care. 2020;24(1):144. doi: 10.1186/s13054-020-02867-w
   PubMed Web of Science ®Google Scholar
• Amaral Pedroso L, Nobre V, Dias Carneiro de Almeida C, et al. Acute kidney injury biomarkers in the critically ill. Clin Chim Acta. 2020;508:170–178. doi: 10.1016/j.cca.2020.05.024
   PubMed Web of Science ®Google Scholar
• Wang Z, Xu J, Zhang Y, et al. Prediction of acute kidney injury incidence following acute type a aortic dissection surgery with novel biomarkers: a prospective observational study. BMC Med. 2023;21:503. doi: 10.1186/s12916-023-03215-9
   PubMed Web of Science ®Google Scholar
• Puthumana J, Hall IE, Reese PP, et al. YKL-40 associates with renal recovery in deceased donor kidney transplantation. J Am Soc Nephrol. 2017;28:661–670. doi: 10.1681/ASN.2016010091
   PubMed Web of Science ®Google Scholar
• Albeltagy ES, Abdul-Mohymen AM, Taha DRA. Early diagnosis of acute kidney injury by urinary YKL-40 in critically ill patients in ICU: a pilot study. Int Urol Nephrol. 2020;52:351–361. doi: 10.1007/s11255-019-02364-2
   PubMed Web of Science ®Google Scholar
• Wang L, Ma P, Chen H, et al. Rapid and ultrasensitive detection of acute kidney injury biomarkers CH3L1 and L-FABP using surface-enhanced Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2023;295:122604. doi: 10.1016/j.saa.2023.122604
   PubMed Web of Science ®Google Scholar
• Olsson SL, Ek B, Björk I. The affinity and kinetics of inhibition of cysteine proteinases by intact recombinant bovine cystatin C. Biochim Biophys Acta. 1999;1432:73–81. doi: 10.1016/s0167-4838(99)00090-4
   PubMedGoogle Scholar
• Zhang Y, Sun L. Cystatin C in Cerebrovascular Disorders. Curr Neurovasc Res. 2017;14(4):406–414. doi: 10.2174/1567202614666171116102504
   PubMed Web of Science ®Google Scholar
• Adingwupu OM, Barbosa ER, Palevsky PM, et al. Cystatin C as a GFR estimation marker in acute and chronic illness: a systematic review. Kidney Med. 2023;5(12):100727. doi: 10.1016/j.xkme.2023.100727
   PubMedGoogle Scholar
• Lees JS, Fabian J, Shlipak MG. Cystatin C should be routinely available for estimating kidney function. Curr Opin Nephrol Hypertens. 2024;33:337–343. doi: 10.1097/MNH.0000000000000980
   PubMed Web of Science ®Google Scholar
• Yang H, Lin C, Zhuang C, et al. Serum cystatin C as a predictor of acute kidney injury in neonates: a meta-analysis. J Pediatr (Rio J). 2022;98:230–240. doi: 10.1016/j.jped.2021.08.005
   PubMed Web of Science ®Google Scholar
• Nakhjavan-Shahraki B, Yousefifard M, Ataei N, et al. Accuracy of cystatin C in prediction of acute kidney injury in children; serum or urine levels: which one works better? A systematic review and meta-analysis. BMC Nephrol. 2017;18:120. doi: 10.1186/s12882-017-0539-0
   PubMed Web of Science ®Google Scholar
• Nateghi Haredasht F, Viaene L, Vens C, et al. Comparison between cystatin c- and creatinine-based estimated glomerular filtration rate in the follow-up of patients recovering from a stage-3 AKI in ICU. J Clin Med. 2022;11:7264. doi: 10.3390/jcm11247264
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu H, Du L, et al. Serum cystatin C predicts AKI and the prognosis of patients in coronary care unit: a prospective, observational study. Kidney Blood Press Res. 2017;42:961–973. doi: 10.1159/000485341
   PubMed Web of Science ®Google Scholar
• Muiru AN, Hsu JY, Zhang X, et al. CRIC study investigators. Risk for chronic kidney disease progression after acute kidney injury: findings from the chronic renal insufficiency cohort study. Ann Intern Med. 2023;176(7):961–968. doi: 10.7326/M22-3617
   PubMed Web of Science ®Google Scholar
• Feng B, Lu Y, Ye L, et al. Mendelian randomization study supports the causal association between serum cystatin C and risk of diabetic nephropathy. Front Endocrinol (Lausanne). 2022;13:1043174. doi: 10.3389/fendo.2022.1043174
   PubMed Web of Science ®Google Scholar
• Liu C, Liu X, He Z, et al. Proenkephalin-A secreted by renal proximal tubules functions as a brake in kidney regeneration. Nat Commun. 2023;14:7167. doi: 10.1038/s41467-023-42929-5
   PubMed Web of Science ®Google Scholar
• Beunders R, Struck J, Wu AHB, et al. Proenkephalin (PENK) as a novel biomarker for kidney function. J Appl Lab Med. 2017;2(3):400–412. doi: 10.1373/jalm.2017.023598
   PubMedGoogle Scholar
• Lin LC, Chuan MH, Liu JH, et al. Proenkephalin as a biomarker correlates with acute kidney injury: a systematic review with meta-analysis and trial sequential analysis. Crit Care. 2023;27:481. doi: 10.1186/s13054-023-04747-5
   PubMed Web of Science ®Google Scholar
• Breidthardt T, Jaeger C, Christ A, et al. Proenkephalin for the early detection of acute kidney injury in hospitalized patients with chronic kidney disease. Eur J Clin Invest. 2018;48:e12999. doi: 10.1111/eci.12999
   PubMed Web of Science ®Google Scholar
• Emmens JE, Ter Maaten JM, Damman K, et al. Proenkephalin, an opioid system surrogate, as a novel comprehensive renal marker in heart failure. Circ Heart Fail. 2019;12:e005544. doi: 10.1161/CIRCHEARTFAILURE.118.005544
   PubMed Web of Science ®Google Scholar
• Siranart N, Laohasurayotin K, Phanthong T, et al. Proenkephalin as a novel prognostic marker in heart failure patients: a systematic review and meta-analysis. Int J Mol Sci. 2023;24(5):4887. doi: 10.3390/ijms24054887
   PubMed Web of Science ®Google Scholar
• Khorashadi M, Beunders R, Pickkers P, et al. Proenkephalin: a new biomarker for glomerular filtration rate and acute kidney injury. Nephron. 2020;144:655–661. doi: 10.1159/000509352
   PubMed Web of Science ®Google Scholar
• Lima C, Gorab DL, Fernandes CR, et al. Role of proenkephalin in the diagnosis of severe and subclinical acute kidney injury during the perioperative period of liver transplantation. Pract Lab Med. 2022;31:e00278. doi: 10.1016/j.plabm.2022.e00278
   PubMedGoogle Scholar
• LaFavers K, Garimella PS. Uromodulin: more than a marker for chronic kidney disease progression. Curr Opin Nephrol Hypertens. 2023;32:271–277. doi: 10.1097/MNH.0000000000000885
   PubMed Web of Science ®Google Scholar
• Tokonami N, Takata T, Beyeler J, et al. Uromodulin is expressed in the distal convoluted tubule, where it is critical for regulation of the sodium chloride cotransporter NCC. Kidney Int. 2018;94:701–715. doi: 10.1016/j.kint.2018.04.021
   PubMed Web of Science ®Google Scholar
• Bächle H, Sekula P, Schlosser P, et al. GCKD investigators. Uromodulin and its association with urinary metabolites: the German chronic kidney disease study. Nephrol Dial Transplant. 2023;38:70–79. doi: 10.1093/ndt/gfac187
   PubMed Web of Science ®Google Scholar
• Mary S, Boder P, Padmanabhan S, et al. Role of uromodulin in salt-sensitive hypertension. Hypertension. 2022;79(11):2419–2429. doi: 10.1161/HYPERTENSIONAHA.122.19888
   PubMed Web of Science ®Google Scholar
• Schaeffer C, Devuyst O, Rampoldi L. Uromodulin: roles in health and disease. Annu Rev Physiol. 2021;83(1):477–501. doi: 10.1146/annurev-physiol-031620-092817
   PubMedGoogle Scholar
• Steubl D, Buzkova P, Ix JH, et al. Association of serum and urinary uromodulin and their correlates in older adults – the cardiovascular health study. Nephrology (Carlton). 2020;25(7):522–526. doi: 10.1111/nep.13688
   PubMed Web of Science ®Google Scholar
• Wolf MTF, Zhang J, Nie M. Uromodulin in mineral metabolism. Curr Opin Nephrol Hypertens. 2019;28:481–489. doi: 10.1097/MNH.0000000000000522
   PubMed Web of Science ®Google Scholar
• Garimella PS, Bartz TM, Ix JH, et al. Urinary uromodulin and risk of urinary tract infections: the cardiovascular health study. Am J Kidney Dis. 2017;69:744–751. doi: 10.1053/j.ajkd.2016.08.022
   PubMed Web of Science ®Google Scholar
• Steubl D, Buzkova P, Garimella PS, et al. Association of serum uromodulin with ESKD and kidney function decline in the elderly: the cardiovascular health study. Am J Kidney Dis. 2019;74:501–509. doi: 10.1053/j.ajkd.2019.02.024
   PubMed Web of Science ®Google Scholar
• Garimella PS, Jaber BL, Tighiouart H, et al. Association of preoperative urinary uromodulin with AKI after cardiac surgery. Clin J Am Soc Nephrol. 2017;12:10–18. doi: 10.2215/CJN.02520316
   PubMed Web of Science ®Google Scholar
• Thielemans R, Speeckaert R, Delrue C, et al. Unveiling the hidden power of uromodulin: a promising potential biomarker for kidney diseases. Diagnostics (Basel). 2023;13:3077. doi: 10.3390/diagnostics13193077
   PubMedGoogle Scholar
• Xing Z, Gong K, Hu N, et al. The Reduction of uromodulin, complement factor H, and their interaction is associated with acute kidney injury to chronic kidney disease transition in a four-time cisplatin-injected rat model. Int J Mol Sci. 2023;24:6636. doi: 10.3390/ijms24076636
   PubMed Web of Science ®Google Scholar
• You R, Zheng H, Xu L, et al. Decreased urinary uromodulin is potentially associated with acute kidney injury: a systematic review and meta-analysis. J Intensive Care. 2021;9:70. doi: 10.1186/s40560-021-00584-2
   PubMed Web of Science ®Google Scholar
• Wen Y, Xu L, Melchinger I, et al.; ASSESS-AKI Consortium. Longitudinal biomarkers and kidney disease progression after acute kidney injury. JCI Insight. 2023;8(9):e167731. doi: 10.1172/jci.insight.167731
   PubMed Web of Science ®Google Scholar
• Patidar KR, Garimella PS, Macedo E, et al. Admission plasma uromodulin and the risk of acute kidney injury in hospitalized patients with cirrhosis: a pilot study. Am J Physiol Gastrointest Liver Physiol. 2019;317:G447–52. doi: 10.1152/ajpgi.00158.2019
   PubMed Web of Science ®Google Scholar
• de Fontnouvelle C, Zappitelli M, Thiessen-Philbrook HR, et al. Biomarkers of eGFR decline after cardiac surgery in children: findings from the ASSESS-AKI study. Pediatr Nephrol. 2023;38:2851–2860. doi: 10.1007/s00467-023-05886-1
   PubMed Web of Science ®Google Scholar
• Thomas SM, Li Q, Faul C. Fibroblast growth factor 23, klotho and heparin. Curr Opin Nephrol Hypertens. 2023;32:313–323. doi: 10.1097/MNH.0000000000000895
   PubMed Web of Science ®Google Scholar
• Sirikul W, Siri-Angkul N, Chattipakorn N, et al. Fibroblast growth factor 23 and osteoporosis: evidence from bench to bedside. Int J Mol Sci. 2022;23:2500. doi: 10.3390/ijms23052500
   PubMed Web of Science ®Google Scholar
• Christov M, Neyra JA, Gupta S, et al. Fibroblast growth factor 23 and klotho in AKI. Semin Nephrol. 2019;39:57–75. doi: 10.1016/j.semnephrol.2018.10.005
   PubMed Web of Science ®Google Scholar
• Lu Y, Xu S, Tang R, et al. A potential link between fibroblast growth factor-23 and the progression of AKI to CKD. BMC Nephrol. 2023;24:87. doi: 10.1186/s12882-023-03125-1
   PubMed Web of Science ®Google Scholar
• Sun S, Liu Z, Chen C, et al. Serum fibroblast growth factor 23 for early detection of acute kidney injury in critical illness. Am J Transl Res. 2021;13(11):12141–12151. PMID: 34956442 PMCID: PMC8661170.
   PubMed Web of Science ®Google Scholar
• Zhang L, Qin W. Research progress of fibroblast growth factor 23 in acute kidney injury. Pediatr Nephrol. 2023;38:2013–2022. doi: 10.1007/s00467-022-05791-z
   PubMed Web of Science ®Google Scholar
• Neyra JA, Hu MC, Moe OW. Fibroblast growth factor 23 and αKlotho in acute kidney injury: current status in diagnostic and therapeutic applications. Nephron. 2020;144:665–672. doi: 10.1159/000509856
   PubMed Web of Science ®Google Scholar
• Kamijo-Ikemori A, Sugaya T, Ichikawa D, et al. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta. 2013;424:104–108. doi: 10.1016/j.cca.2013.05.020
   PubMed Web of Science ®Google Scholar
• Eguchi A, Iwasa M. The role of elevated liver-type fatty acid-binding proteins in liver diseases. Pharm Res. 2021;38(1):89–95. doi: 10.1007/s11095-021-02998-x
   PubMed Web of Science ®Google Scholar
• Karvellas CJ, Speiser JL, Tremblay M, et al. US Acute Liver Failure Study Group. Elevated serum liver-type fatty acid binding protein levels in non-acetaminophen acute liver failure patients with organ dysfunction. Dig Dis Sci. 2021;66:273–283. doi: 10.1007/s10620-020-06166-w
   PubMed Web of Science ®Google Scholar
• Katoh H, Nozue T, Kimura Y, et al. Elevation of urinary liver-type fatty acid-binding protein as predicting factor for occurrence of contrast-induced acute kidney injury and its reduction by hemodiafiltration with blood suction from right atrium. Heart Vessels. 2014;29(2):191–197. doi: 10.1007/s00380-013-0347-9
   PubMed Web of Science ®Google Scholar
• Ohata K, Sugaya T, Nguyen HN, et al. Urinary liver-type fatty acid binding protein is increased in the early stages of the disease with a risk of acute kidney injury induced by histone. Nephrology (Carlton). 2023;28(6):345–355. doi: 10.1111/nep.14162
   PubMed Web of Science ®Google Scholar
• Cheng Y, Jian JM, He CY, et al. The correlations of plasma liver-type fatty acid-binding protein with amyloid-β and tau levels in patients with alzheimer’s disease. J Alzheimers Dis. 2022;88(1):375–383. doi: 10.3233/JAD-220126
   PubMed Web of Science ®Google Scholar
• Sunayama T, Yatsu S, Matsue Y, et al. Urinary liver-type fatty acid-binding protein as a prognostic marker in patients with acute heart failure. ESC Heart Fail. 2022;9(1):442–449. doi: 10.1002/ehf2.13730
   PubMed Web of Science ®Google Scholar
• Zhang L, Xue S, Wu M, et al. Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: a meta-analysis. Front Med (Lausanne). 2022;9:914587. doi: 10.3389/fmed.2022.914587
   PubMed Web of Science ®Google Scholar
• Chiang TH, Yo CH, Lee GH, et al. Accuracy of liver-type fatty acid-binding protein in predicting acute kidney injury: a meta-analysis. J Appl Lab Med. 2022;7(2):421–436. doi: 10.1093/jalm/jfab092.
   PubMedGoogle Scholar
• Mitsides N, Mitra V, Saha A, et al. Urinary liver-type fatty acid binding protein, a biomarker for disease progression, dialysis and overall mortality in chronic kidney disease. J Pers Med. 2023;13(10):1481. doi: 10.3390/jpm13101481
   PubMed Web of Science ®Google Scholar
• Moriyama T, Hagihara S, Shiramomo T, et al. The protective effect of human atrial natriuretic peptide on renal damage during cardiac surgery. J Anesth. 2017;31:163–169. doi: 10.1007/s00540-016-2284-0
   PubMed Web of Science ®Google Scholar
• Koo TY, Jeong JC, Lee Y, et al. Pre-transplant evaluation of donor urinary biomarkers can predict reduced graft function after deceased donor kidney transplantation. Medicine (Baltimore). 2016;95(11):e3076. doi: 10.1097/MD.0000000000003076
   PubMed Web of Science ®Google Scholar
• Weiss R, Meersch M, Wempe C, et al. Recombinant alpha-1-microglobulin (RMC-035) to prevent acute kidney injury in cardiac surgery patients: phase 1b evaluation of safety and pharmacokinetics. Kidney Int Rep. 2023;8(5):980–988. doi: 10.1016/j.ekir.2023.02.1071
   PubMedGoogle Scholar
• Hansson M, Gustafsson R, Jacquet C, et al. Cystatin C and α-1-microglobulin predict severe acute kidney injury in patients with hemorrhagic fever with renal syndrome. Pathogens. 2020;9(8):666. doi: 10.3390/pathogens9080666
   PubMed Web of Science ®Google Scholar
• Amatruda JG, Estrella MM, Garg AX, et al. TRIBE-AKI Consortium. Urine alpha-1-microglobulin levels and acute kidney injury, mortality, and cardiovascular events following cardiac surgery. Am J Nephrol. 2021;52:673–683. doi: 10.1159/000518240
   PubMed Web of Science ®Google Scholar
• Van den Eynde J, Salaets T, Louw JJ, et al. Persistent markers of kidney injury in children who developed acute kidney injury after pediatric cardiac surgery: a prospective cohort study. J Am Heart Assoc. 2022;11:e024266. doi: 10.1161/JAHA.121.024266
   PubMed Web of Science ®Google Scholar
• Ho J, Tangri N, Komenda P, et al. Urinary, plasma, and serum biomarkers’ utility for predicting acute kidney injury associated with cardiac surgery in adults: a meta-analysis. Am J Kidney Dis. 2015;66(6):993–1005. doi: 10.1053/j.ajkd.2015.06.018
   PubMed Web of Science ®Google Scholar
• Devarajan P, Krawczeski CD, Nguyen MT, et al. Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. Am J Kidney Dis. 2010;56(4):632–642. doi: 10.1053/j.ajkd.2010.04.014
   PubMed Web of Science ®Google Scholar
• Marzuillo P, Di Sessa A, Palma PL, et al. Renal involvement in children with type 2 diabetes mellitus onset: a pilot study. Children (Basel). 2021;8(8):627. doi: 10.3390/children8080627
   PubMed Web of Science ®Google Scholar
• Susianti H, Asmoro AA, Sujarwoto, et al. Acute kidney injury prediction model using cystatin-c, beta-2 microglobulin, and neutrophil gelatinase-associated lipocalin biomarker in sepsis patients. Int J Nephrol Renovasc Dis. 2024;17:105–112. doi: 10.2147/IJNRD.S450901
   PubMed Web of Science ®Google Scholar
• Song SM, Jeon J, Jang HR, et al. Acute kidney injury in bortezomib-treated patients with multiple myeloma. Nephrol Dial Transplant. 2023;38(9):2077–2085. doi: 10.1093/ndt/gfad016
   PubMed Web of Science ®Google Scholar
• Puthiyottil D, Priyamvada PS, Kumar MN, et al. Role of urinary beta 2 microglobulin and kidney injury molecule-1 in predicting kidney function at one year following acute kidney injury. Int J Nephrol Renovasc Dis. 2021;14:225–234. doi: 10.2147/IJNRD.S319933
   PubMed Web of Science ®Google Scholar
• Jalali SZ, Enteshari M, Saadat F. Reciprocal assessment of urinary beta-2-microglobulin and BUN levels in renal dysfunction of neonates with birth asphyxia. J Matern Fetal Neonatal Med. 2022;35(25):6624–6630. doi: 10.1080/14767058.2021.1918667
   PubMed Web of Science ®Google Scholar
• Lu HY, Ning XY, Chen YQ, et al. Predictive value of serum creatinine, blood urea nitrogen, uric acid, and β2-microglobulin in the evaluation of acute kidney injury after orthotopic liver transplantation. Chin Med J (Engl). 2018;131(9):1059–1066. doi: 10.4103/0366-6999.230726
   PubMed Web of Science ®Google Scholar
• Beitland S, Nakstad ER, Berg JP, et al. Urine β-2-microglobulin, osteopontin, and trefoil factor 3 may early predict acute kidney injury and outcome after cardiac arrest. Crit Care Res Pract. 2019;2019:4384796. doi: 10.1155/2019/4384796
   PubMed Web of Science ®Google Scholar
• Jaswanth C, Priyamvada PS, Zachariah B, et al. Short-term changes in urine beta 2 microglobulin following recovery of acute kidney injury resulting from snake envenomation. Kidney Int Rep. 2019;4(5):667–673. doi: 10.1016/j.ekir.2019.01.016
   PubMed Web of Science ®Google Scholar
• Barton KT, Kakajiwala A, Dietzen DJ, et al. Using the newer kidney disease: improving global outcomes criteria, beta-2-microglobulin levels associate with severity of acute kidney injury. Clin Kidney J. 2018;11(6):797–802. doi: 10.1093/ckj/sfy056
   PubMed Web of Science ®Google Scholar
• Arend WP, Palmer G, IL-1 GC. IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223(1):20–38. doi: 10.1111/j.1600-065X.2008.00624.x
   PubMedGoogle Scholar
• Luan J, Fu J, Jiao C, et al. IL-18 deficiency ameliorates the progression from AKI to CKD. Cell Death Dis. 2022;13(11):957. doi: 10.1038/s41419-022-05394-4
   PubMed Web of Science ®Google Scholar
• Al-Saegh Rm A, Mohanad MA, Khudhair NJ, et al. Using urinary interleukin-18 as a potential marker for early detection of acute kidney injury in intensive care unit. Saudi J Kidney Dis Transpl. 2021;32(2):341–347. doi: 10.4103/1319-2442.335445
   PubMed Web of Science ®Google Scholar
• Qin Z, Li H, Jiao P, et al. The value of urinary interleukin-18 in predicting acute kidney injury: a systematic review and meta-analysis. Ren Fail. 2022;44(1):1717–1731. doi: 10.1080/0886022X.2022.2133728
   PubMed Web of Science ®Google Scholar
• Gan J, Zhou X. Comparison of urine neutrophil gelatinase-associated lipocalin and interleukin-18 in prediction of acute kidney injury in adults. Medicine (Baltimore). 2018;97:e12570. doi: 10.1097/MD.0000000000012570
   PubMed Web of Science ®Google Scholar
• Puthumana J, Ariza X, Belcher JM, et al. Urine interleukin 18 and lipocalin 2 are biomarkers of acute tubular necrosis in patients with cirrhosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(7):1003–13.e3. doi: 10.1016/j.cgh.2016.11.035
   PubMed Web of Science ®Google Scholar
• Li Y, Fu C, Zhou X, et al. Urine interleukin-18 and cystatin-C as biomarkers of acute kidney injury in critically ill neonates. Pediatr Nephrol. 2012;27:851–860. doi: 10.1007/s00467-011-2072-x
   PubMed Web of Science ®Google Scholar
• Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021;70:1978–1988. doi: 10.1136/gutjnl-2021-324855
   PubMed Web of Science ®Google Scholar
• Shi W, Wan TT, Li HH, et al. Blockage of S100A8/A9 ameliorates septic nephropathy in mice. Front Pharmacol. 2023;14:1172356. doi: 10.3389/fphar.2023.1172356
   PubMed Web of Science ®Google Scholar
• Tan X, Zheng X, Huang Z, et al. Involvement of S100A8/A9-TLR4-NLRP3 inflammasome pathway in contrast-induced acute kidney injury. Cell Physiol Biochem. 2017;43:209–222. doi: 10.1159/000480340
   PubMedGoogle Scholar
• John JS, Deepthi RV, Rebekah G, et al. Usefulness of urinary calprotectin as a novel marker differentiating functional from structural acute kidney injury in the critical care setting. J Nephrol. 2023;36:695–704. doi: 10.1007/s40620-022-01534-3
   PubMed Web of Science ®Google Scholar
• Heller F, Frischmann S, Grünbaum M, et al. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol. 2011;6(10):2347–2355. doi: 10.2215/CJN.02490311
   PubMed Web of Science ®Google Scholar
• Seibert FS, Rosenberger C, Mathia S, et al. Urinary calprotectin differentiates between prerenal and intrinsic acute renal allograft failure. Transplantation. 2017;101:387–394. doi: 10.1097/TP.0000000000001124
   PubMed Web of Science ®Google Scholar
• Chen JJ, Fan PC, Kou G, et al. Meta-analysis: urinary calprotectin for discrimination of intrinsic and prerenal acute kidney injury. J Clin Med. 2019;8(1):74. doi: 10.3390/jcm8010074
   PubMed Web of Science ®Google Scholar
• Vakili M, Fahimi D, Esfahani ST, et al. Comparative analysis between urinary calprotectin and serum creatinine for early detection of intrinsic acute kidney injury. Indian J Nephrol. 2021;31:353–357. doi: 10.4103/ijn.IJN_83_20
   PubMed Web of Science ®Google Scholar
• Kim AJ, Ro H, Kim H, et al. Klotho and S100A8/A9 as discriminative markers between pre-renal and intrinsic acute kidney injury. PLoS One. 2016;11(1):e0147255. doi: 10.1371/journal.pone.0147255
   PubMed Web of Science ®Google Scholar
• Seibert FS, Heringhaus A, Pagonas N, et al. Biomarkers in the prediction of contrast media induced nephropathy – the BITCOIN study. PLoS One. 2020;15(7):e0234921. doi: 10.1371/journal.pone.0234921
   PubMed Web of Science ®Google Scholar
• Mourtada J, Thibaudeau C, Wasylyk B, et al. The multifaceted role of human dickkopf-3 (DKK-3) in development, immune modulation and cancer. Cells. 2023;13:75. doi: 10.3390/cells13010075
   PubMed Web of Science ®Google Scholar
• Busceti CL, Carrizzo A, Bianchi F, et al. Role of dickkopf-3 in blood pressure regulation in mice and hypertensive rats. Circ Res. 2023;132:1489–1504. doi: 10.1161/CIRCRESAHA.122.321744
   PubMed Web of Science ®Google Scholar
• Fang X, Hu J, Chen Y, et al. Dickkopf-3: current knowledge in kidney diseases. Front Physiol. 2020;11:533344. doi: 10.3389/fphys.2020.533344
   PubMed Web of Science ®Google Scholar
• Hu J, Zhou Y, Huang H, et al. Prediction of urinary dickkopf-3 for AKI, sepsis-associated AKI, and PICU mortality in children. Pediatr Res. 2023;93:1651–1658. doi: 10.1038/s41390-022-02269-4
   PubMed Web of Science ®Google Scholar
• Roscigno G, Quintavalle C, Biondi-Zoccai G, et al. Urinary dickkopf-3 and contrast-associated kidney damage. J Am Coll Cardiol. 2021;77:2667–2676. doi: 10.1016/j.jacc.2021.03.330
   PubMed Web of Science ®Google Scholar
• Xing H, Jiang Z, Wu Y, et al. The role of urinary dickkopf-3 in the prediction of acute kidney injury: a systematic review meta-analysis. Int Urol Nephrol. 2023;55:3175–3188. doi: 10.1007/s11255-023-03593-2
   PubMed Web of Science ®Google Scholar
• Peschard VG, Scherzer R, Katz R, et al. Association of urinary dickkopf-3 levels with cardiovascular events and kidney disease progression in systolic blood pressure intervention trial. Kidney360. 2024;5(5):690–697. doi: 10.34067/KID.0000000000000413
   PubMedGoogle Scholar
• Schunk SJ, Zarbock A, Meersch M, et al. Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study. Lancet. 2019;394:488–496. doi: 10.1016/S0140-6736(19)30769-X
   PubMed Web of Science ®Google Scholar
• Singh R, Watchorn JC, Zarbock A, et al. Prognostic biomarkers and AKI: potential to enhance the identification of post-operative patients at risk of loss of renal function. Res Rep Urol. 2024;16:65–78. doi: 10.2147/RRU.S385856
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson WG, Seo DW. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med. 2005;11:97–103. doi: 10.1016/j.molmed.2005.01.007
   PubMed Web of Science ®Google Scholar
• Akalya K, Murali TM, Vathsala A, et al. Elevated urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein-7 predict drug-induced acute kidney injury. Curr Drug Metab. 2022;23:223–232. doi: 10.2174/1389200223666220425111931
   PubMed Web of Science ®Google Scholar
• Sakyi SA, Ephraim RKD, Adoba P, et al. Tissue inhibitor metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) best predicts the development of acute kidney injury. Heliyon. 2021;7:e07960. doi: 10.1016/j.heliyon.2021.e07960
   PubMed Web of Science ®Google Scholar
• Maizel J, Daubin D, Vong LV, et al. Urinary TIMP2 and IGFBP7 identifies high risk patients of short-term progression from mild and moderate to severe acute kidney injury during septic shock: a prospective cohort study. Dis Markers. 2019;2019:3471215. doi: 10.1155/2019/3471215
   PubMed Web of Science ®Google Scholar
• Abouhadid MA, Gawad TAA, Gebaly HHE, et al. Urinary tissue inhibitor of metalloproteinase-2 as an early predictor for acute kidney injury in critically ill children. Int J Health Sci (Qassim). 2023;17(4):22–28. PMID: 37416842 PMCID: PMC10321466.
   PubMedGoogle Scholar
• Xie Y, Ankawi G, Yang B, et al. Tissue inhibitor metalloproteinase-2 (TIMP-2) • IGF-binding protein-7 (IGFBP7) levels are associated with adverse outcomes in patients in the intensive care unit with acute kidney injury. Kidney International. 2019;95(6):1486–1493. doi: 10.1016/j.kint.2019.01.020
   PubMed Web of Science ®Google Scholar
• Cho WY, Lim SY, Yang JH, et al. Urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 as biomarkers of patients with established acute kidney injury. Korean J Intern Med. 2020;35:662–671. doi: 10.3904/kjim.2018.266
   PubMed Web of Science ®Google Scholar
• Bayless RL, Moore AR, Hassel DM, et al. Equine urinary N-acetyl-β-D-glucosaminidase assay validation and correlation with other markers of kidney injury. J Vet Diagn Invest. 2019;31:688–695. doi: 10.1177/1040638719867124
   PubMed Web of Science ®Google Scholar
• Cheng P, Miao Q, Huang J, et al. Multiplex optical urinalysis for early detection of drug-induced kidney injury. Anal Chem. 2020;92(8):6166–6172. doi: 10.1021/acs.analchem.0c00989
   PubMed Web of Science ®Google Scholar
• Chaudhary K, Vaid A, Duffy Á, et al. Utilization of deep learning for subphenotype identification in sepsis-associated acute kidney injury. Clin J Am Soc Nephrol. 2020;15:1557–1565. doi: 10.2215/CJN.09330819
   PubMed Web of Science ®Google Scholar
• Emlet DR, Pastor-Soler N, Marciszyn A, et al. Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells. Am J Physiol Renal Physiol. 2017;312:F284–96. doi: 10.1152/ajprenal.00271.2016
   PubMed Web of Science ®Google Scholar
• Hu BC, Zhu JW, Wu GH, et al. Auto- and paracrine rewiring of NIX-mediated mitophagy by insulin-like growth factor-binding protein 7 in septic AKI escalates inflammation-coupling tubular damage. Life Sci. 2023;322:121653. doi: 10.1016/j.lfs.2023.121653
   PubMed Web of Science ®Google Scholar
• Yu JT, Hu XW, Yang Q, et al. Insulin-like growth factor binding protein 7 promotes acute kidney injury by alleviating poly ADP ribose polymerase 1 degradation. Kidney Int. 2022;102:828–844. doi: 10.1016/j.kint.2022.05.026
   PubMed Web of Science ®Google Scholar
• Meersch M, Schmidt C, Van Aken H, et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLOS ONE. 2014;9(3):e93460. doi: 10.1371/journal.pone.0093460
   PubMed Web of Science ®Google Scholar
• Ganda IJ, Kasri Y, Susanti M, et al. Kidney injury molecule type-1, interleukin-18, and insulin-like growth factor binding protein 7 levels in urine to predict acute kidney injury in pediatric sepsis. Front Pediatr. 2022;10:1024713. doi: 10.3389/fped.2022.1024713
   PubMed Web of Science ®Google Scholar
• Hatton GE, Wang YW, Isbell KD, et al. Urinary cell cycle arrest proteins urinary tissue inhibitor of metalloprotease 2 and insulin-like growth factor binding protein 7 predict acute kidney injury after severe trauma: a prospective observational study. J Trauma Acute Care Surg. 2020;89:761–767. doi: 10.1097/TA.0000000000002864
   PubMed Web of Science ®Google Scholar
• La AM, Gunning S, Trevino SA, et al. Real-world use of AKI biomarkers: a quality improvement project using urinary tissue inhibitor metalloprotease-2 and insulin-like growth factor binding protein 7 ([TIMP-2]*[IGFBP7]). Am J Nephrol. 2023;54:281–290. doi: 10.1159/000531641
   PubMed Web of Science ®Google Scholar
• Liu C, Lu X, Mao Z, et al. The diagnostic accuracy of urinary [TIMP-2]·[IGFBP7] for acute kidney injury in adults: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017;96:e7484. doi: 10.1097/MD.0000000000007484
   PubMed Web of Science ®Google Scholar
• Jia HM, Huang LF, Zheng Y, et al. Diagnostic value of urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 for acute kidney injury: a meta-analysis. Crit Care. 2017;21:77. doi: 10.1186/s13054-017-1660-y
   PubMed Web of Science ®Google Scholar
• McCullough PA, Ostermann M, Forni LG, et al. The sapphire investigators. serial urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 and the prognosis for acute kidney injury over the course of critical illness. Cardiorenal Med. 2019;9:358–369. doi: 10.1159/000502837
   PubMed Web of Science ®Google Scholar
• Zafar Mohtashami A, Hadian B, Mahmoudi GA, et al. The application of urinary NGAL measurement for early detection of AKI in hospitalized patients with poisoning. Iran J Kidney Dis. 2020;14:206–211. PMID: 32361697.
   PubMed Web of Science ®Google Scholar
• Urbschat A, Gauer S, Paulus P, et al. Serum and urinary NGAL but not KIM-1 raises in human postrenal AKI. Eur J Clin Invest. 2014;44:652–659. doi: 10.1111/eci.12283
   PubMed Web of Science ®Google Scholar
• Brewin A, Sriprasad S, Somani B. The use of neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic and prognostic biomarker in urinary tract obstruction: a systematic review. Curr Urol Rep. 2022;23(8):155–163. doi: 10.1007/s11934-022-01098-6
   PubMed Web of Science ®Google Scholar
• Sun Q, Kang Z, Li Z, et al. Urinary NGAL, IGFBP-7, and TIMP-2: novel biomarkers to predict contrast medium-induced acute kidney injury in children. Ren Fail. 2022;44(1):1201–1206. doi: 10.1080/0886022X.2022.2075277
   PubMed Web of Science ®Google Scholar
• Ishak SKI, Aguizy FE, Elsebaie EH, et al. Role of urinary NGAL and microalbuminuria in the detection of subclinical acute kidney injury in pediatric intensive care unit and diabetic children. Pediatr Med Chir. 2022;44(2). doi: 10.4081/pmc.2022.285
   PubMedGoogle Scholar
• Singer E, Schrezenmeier EV, Elger A, et al. Urinary NGAL-Positive acute kidney injury and poor long-term outcomes in hospitalized patients. Kidney Int Rep. 2016;1(3):114–124. doi: 10.1016/j.ekir.2016.07.003
   PubMedGoogle Scholar
• Bullen AL, Katz R, Jotwani V, et al. Biomarkers of kidney tubule health, CKD progression, and acute kidney injury in SPRINT (systolic blood pressure intervention trial) participants. Am J Kidney Dis. 2021;78(3):361–68.e1. doi: 10.1053/j.ajkd.2021.01.021
   PubMed Web of Science ®Google Scholar
• Kiernan EA, Hu D, Philbrook HT, et al. Urinary biomarkers and kidney injury in VA NEPHRON-D: phenotyping acute kidney injury in clinical trials. Am J Kidney Dis. 2024;83(2):151–161. doi: 10.1053/j.ajkd.2023.07.012
   PubMed Web of Science ®Google Scholar
• Wen Y, Thiessen-Philbrook H, Moledina DG, et al. Considerations in controlling for urine concentration for biomarkers of kidney disease progression after acute kidney injury. Kidney Int Rep. 2022;7:1502–1513. doi: 10.1016/j.ekir.2022.03.026
   PubMed Web of Science ®Google Scholar
• Da Y, Akalya K, Murali T, et al. Serial quantification of urinary protein biomarkers to predict drug-induced acute kidney injury. Curr Drug Metab. 2019;20(8):656–664. doi: 10.2174/1389200220666190711114504
   PubMed Web of Science ®Google Scholar
• Pan HC, Yang SY, Chiou TT, et al. Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis. Crit Care. 2022;26(1):349. doi: 10.1186/s13054-022-04223-6
   PubMed Web of Science ®Google Scholar
• Liu C, Debnath N, Mosoyan G, et al. Systematic review and meta-analysis of plasma and urine biomarkers for CKD outcomes. J Am Soc Nephrol. 2022;33(9):1657–1672. doi: 10.1681/ASN.2022010098 PMID: 35858701
   PubMed Web of Science ®Google Scholar